Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

Journavx, a non-opioid treatment for moderate to severe acute pain, received FDA approval with a broad label. The drug’s pricing strategy, set at a daily maintenance price of $31, has exceeded ...

Journavx, a non-opioid treatment for moderate to severe acute pain, received FDA approval with a broad label. The drug’s pricing strategy, set at a daily maintenance price of $31, has exceeded ...

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...

Vertex has been a phenomenal growth stock, and with the FDA approval of its non-opioid pain medication Journavx in January, more growth could be on the way. The company's highly profitable ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...